Etrasimod is an S1P receptors modulator used to treat moderate to severely active ulcerative colitis in adults. Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors.
- Mechanism
- Curator reviewed · 1 reference
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5 (S1P1,4,5). Etrasimod has minimal activity on S1P3 (25-fold lower than Cmax at the recommended dose) and no activity on S1P2. Etrasimod partially and reversibly blocks the capacity of lymphocytes to egress from lymphoid organs, reducing the number of lymphocytes in peripheral blood. The mechanism by which etrasimod exerts therapeutic effects in UC is unknown but may involve the reduction of lymphocyte migration into the intestines.
- Primary indication
- Etrasimod is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.Curator reviewed · 6 structured indications
- Formula / weight
- C26H26F3NO3 · 457.493 g/mol (avg)
- First approval
- Canada, 2024 · United States, 2023 · European Union, 2024
- Code names
- APD334
- Brand names
Resolves to
MVGWUTBTXDYMND-QGZVFWFLSA-NSMILESOC(=O)C[C@H]1CCC2=C1NC1=C2C=C(OCC2=CC(=C(C=C2)C2CCCC2)C(F)(F)F)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Etrasimod, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account